CR7868A - Combinacion para el tratamiento del trastorno por deficit de atencion con hiperactividad - Google Patents

Combinacion para el tratamiento del trastorno por deficit de atencion con hiperactividad

Info

Publication number
CR7868A
CR7868A CR7868A CR7868A CR7868A CR 7868 A CR7868 A CR 7868A CR 7868 A CR7868 A CR 7868A CR 7868 A CR7868 A CR 7868A CR 7868 A CR7868 A CR 7868A
Authority
CR
Costa Rica
Prior art keywords
hyperactivity
deficit
disorder
care
treatment
Prior art date
Application number
CR7868A
Other languages
English (en)
Inventor
Edward Jr Groppi Vincent
Jon Jacobsen Eric
Kenneth Myers Jason
Walter Piotrowski David
Nelson Rogers Bruce
Patrick Walker Daniel
Gregory Wishka Donn
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of CR7868A publication Critical patent/CR7868A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a composiciones y a procedimientos para tratar ADHD con un agonista completo de nAChR a7 y psicoestimulantes y/o inhibidores de la recaptacion de monoamina.
CR7868A 2002-12-11 2005-06-10 Combinacion para el tratamiento del trastorno por deficit de atencion con hiperactividad CR7868A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43258602P 2002-12-11 2002-12-11

Publications (1)

Publication Number Publication Date
CR7868A true CR7868A (es) 2005-07-08

Family

ID=32507968

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7868A CR7868A (es) 2002-12-11 2005-06-10 Combinacion para el tratamiento del trastorno por deficit de atencion con hiperactividad

Country Status (23)

Country Link
US (1) US20050107425A1 (es)
EP (1) EP1572300A1 (es)
JP (1) JP2006510663A (es)
KR (1) KR20050085538A (es)
CN (1) CN1735441A (es)
AP (1) AP2005003336A0 (es)
AU (1) AU2003283656A1 (es)
BR (1) BR0317229A (es)
CA (1) CA2509142A1 (es)
CO (1) CO5700801A2 (es)
CR (1) CR7868A (es)
EA (1) EA200500783A1 (es)
EC (1) ECSP055852A (es)
HR (1) HRP20050522A2 (es)
IS (1) IS7858A (es)
MA (1) MA27606A1 (es)
MX (1) MXPA05006336A (es)
NO (1) NO20053185L (es)
OA (1) OA12969A (es)
PL (1) PL377552A1 (es)
TN (1) TNSN05158A1 (es)
WO (1) WO2004052461A1 (es)
ZA (1) ZA200504338B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0310867D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
EP1735306A2 (en) 2004-03-25 2006-12-27 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
US20100056600A1 (en) * 2007-03-28 2010-03-04 Soren Ebdrup 11beta-hsd1 active compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
KR20100137473A (ko) * 2008-02-19 2010-12-30 아돌로 코포레이션 동통 치료를 위한 벨록세핀, 이의 거울상이성질체, 및 이의 유사체
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
PE20170923A1 (es) 2010-05-17 2017-07-12 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado
WO2012015715A1 (en) 2010-07-27 2012-02-02 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators
EP3461481A1 (en) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
KR102629135B1 (ko) 2021-08-19 2024-01-29 단국대학교 천안캠퍼스 산학협력단 Kds2010을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
KR102684933B1 (ko) 2021-08-20 2024-07-16 단국대학교 천안캠퍼스 산학협력단 주의력결핍 과잉행동장애의 진단을 위한 gat-3의 용도
KR102597711B1 (ko) 2021-08-20 2023-11-06 단국대학교 천안캠퍼스 산학협력단 Snap5114을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
WO2023022269A1 (ko) 2021-08-20 2023-02-23 단국대학교 천안캠퍼스 산학협력단 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
EA200500783A1 (ru) 2005-12-29
JP2006510663A (ja) 2006-03-30
CN1735441A (zh) 2006-02-15
MXPA05006336A (es) 2005-08-26
NO20053185L (no) 2005-08-17
HRP20050522A2 (en) 2005-12-31
EP1572300A1 (en) 2005-09-14
AU2003283656A1 (en) 2004-06-30
CO5700801A2 (es) 2006-11-30
AP2005003336A0 (en) 2005-06-30
ECSP055852A (es) 2005-09-20
KR20050085538A (ko) 2005-08-29
US20050107425A1 (en) 2005-05-19
NO20053185D0 (no) 2005-06-29
IS7858A (is) 2005-05-23
ZA200504338B (en) 2006-07-26
TNSN05158A1 (fr) 2007-05-14
BR0317229A (pt) 2005-11-01
MA27606A1 (fr) 2005-11-01
PL377552A1 (pl) 2006-02-06
OA12969A (en) 2006-10-13
WO2004052461A1 (en) 2004-06-24
CA2509142A1 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
CR7868A (es) Combinacion para el tratamiento del trastorno por deficit de atencion con hiperactividad
ECSP10010007A (es) Tratamiento con ligandos alpha-7-selectivos
ECSP099525A (es) Inhibidores de mek
ATE554114T1 (de) Copolymer mit zwitterionischen einheiten und anderen einheiten, das copolymer umfassende zusammensetzung und verwendung
ECSP21026021A (es) Moduladores de la expresión de pnpla3
IL202106A0 (en) Gaboxadol for treating depression and other affective disorders
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CL2012000097A1 (es) Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.
PA8571901A1 (es) Nueva composicion farmaceutica
AR072115A1 (es) Composiciones para el tratamiento de materiales y metodos para tratarlos
EA200501802A1 (ru) Сочетание аналептина модафинила и антидепрессанта для лечения депресии
BRPI0411175A (pt) combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão
DE60313886D1 (de) Zusammensetzung von einem ppar-alpha agonisten und metformin zur behandlung von obesitas
DK1554240T3 (da) Substituerede tetraliner og indaner og deres anvendelse
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
BRPI0506631B8 (pt) combinações, composição farmacêutica e usos das combinações
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
EA200870533A1 (ru) Производные 3-(1н-индол-3-ил)индан-1-иламина для лечения депрессии и тревожности
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
UY31424A1 (es) Compuestos de 2,3-dihidro-benzofurano
BRPI0603759A (pt) associação entre agomelatina e um inibidor de recaptação de noradrenalina, e composições farmacêuticas contendo-a
EA200600183A1 (ru) Сочетание ингибитора обратного захвата серотонина и агомелатина
ATE546157T1 (de) Anti-pecam-therapie zur unterdrückung von metastasen
ATE516704T1 (de) Tiermodell für adhd

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)